GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syn-Tech Chem & Pharm Co Ltd (ROCO:1777) » Definitions » EBIT

Syn-Tech Chem & Pharm Co (ROCO:1777) EBIT : NT$347 Mil (TTM As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Syn-Tech Chem & Pharm Co EBIT?

Syn-Tech Chem & Pharm Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was NT$110 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was NT$347 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Syn-Tech Chem & Pharm Co's annualized ROC % for the quarter that ended in Mar. 2024 was 11.88%. Syn-Tech Chem & Pharm Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 24.12%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Syn-Tech Chem & Pharm Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 9.59%.


Syn-Tech Chem & Pharm Co EBIT Historical Data

The historical data trend for Syn-Tech Chem & Pharm Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syn-Tech Chem & Pharm Co EBIT Chart

Syn-Tech Chem & Pharm Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 208.31 236.41 203.62 361.16 319.51

Syn-Tech Chem & Pharm Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 83.19 85.68 117.12 33.52 110.50

Competitive Comparison of Syn-Tech Chem & Pharm Co's EBIT

For the Biotechnology subindustry, Syn-Tech Chem & Pharm Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syn-Tech Chem & Pharm Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syn-Tech Chem & Pharm Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Syn-Tech Chem & Pharm Co's EV-to-EBIT falls into.



Syn-Tech Chem & Pharm Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$347 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Syn-Tech Chem & Pharm Co  (ROCO:1777) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Syn-Tech Chem & Pharm Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=298.452 * ( 1 - 20% )/( (2069.092 + 1951.139)/ 2 )
=238.7616/2010.1155
=11.88 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2900.891 - 164.877 - ( 666.922 - max(0, 507.009 - 1420.228+666.922))
=2069.092

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2840.663 - 300.753 - ( 588.771 - max(0, 514.454 - 1385.246+588.771))
=1951.139

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Syn-Tech Chem & Pharm Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=441.984/( ( (1452.669 + max(437.111, 0)) + (1431.002 + max(343.396, 0)) )/ 2 )
=441.984/( ( 1889.78 + 1774.398 )/ 2 )
=441.984/1832.089
=24.12 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(131.548 + 459.975 + 10.496) - (164.877 + 0 + 0.031000000000006)
=437.111

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(152.528 + 481.116 + 10.689) - (300.753 + 0 + 0.18399999999997)
=343.396

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Syn-Tech Chem & Pharm Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=346.816/3617.639
=9.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Syn-Tech Chem & Pharm Co EBIT Related Terms

Thank you for viewing the detailed overview of Syn-Tech Chem & Pharm Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Syn-Tech Chem & Pharm Co (ROCO:1777) Business Description

Traded in Other Exchanges
N/A
Address
168 Kai Yuan Road, Hsin Ying, TWN, 730
Syn-Tech Chem & Pharm Co Ltd is engaged in the production, processing, and distribution of active pharmaceutical ingredients (APIs) in Taiwan. some of its products consist of anti-inflammatory drugs, antimicrobials, spirit stabilizers, cardiovascular agents and others.

Syn-Tech Chem & Pharm Co (ROCO:1777) Headlines

No Headlines